Evidence map›Paper›PMID 42396557›Full record

ArticleIBRO neuroscience reports2026

Reza Yousefi, Niloufar Darbandi, Majid Komijani

Abstract read
In one paragraph

Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Reza YousefiDepartment of Biology, Faculty of Sciencse, Arak University, Arak 384817758, Iran.
Niloufar DarbandiDepartment of Biology, Faculty of Sciencse, Arak University, Arak 384817758, Iran.
Majid KomijaniDepartment of Biology, Faculty of Sciencse, Arak University, Arak 384817758, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cognitive impairment associated with neurodegenerative conditions is frequently driven by oxidative stress and neuroinflammation arising from metabolic and environmental insults. Streptozotocin (STZ) and aluminum chloride (AlCl₃) are widely used to induce experimental models of cognitive dysfunction through distinct pathogenic mechanisms. This study evaluated the neuroprotective effects of the probiotic Materials and Methods: Adult male Wistar rats were divided into five groups: control, STZ, AlCl₃, probiotic + STZ, and probiotic + AlCl₃. Rats received intracerebroventricular STZ or saline, AlCl₃ in drinking water, and daily oral gavage of Results: STZ and AlCl₃ administration induced significant memory impairment, increased oxidative stress and pro-inflammatory cytokines, and reduced the number of healthy hippocampal neurons. Probiotic treatment significantly improved memory performance, reduced lipid peroxidation and inflammatory markers, enhanced antioxidant defenses, decreased aluminum accumulation, and preserved neuronal integrity in the hippocampus. Conclusion: Oral administration of

Indexed as

Aluminum chlorideCognitive impairmentLactobacillus acidophilusNeuroinflammationOxidative stressStreptozotocin

Identifiers

PMID42396557
PMCPMC13324680

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.